


Edited by Nathan Brown

 WILEY-VCH

# Bioisosteres in Medicinal Chemistry



**Volume 54**

Series Editors:  
R. Mannhold,  
H. Kubinyi,  
G. Folkers



*Edited by Nathan Brown*

## **Bioisosteres in Medicinal Chemistry**



**WILEY-  
VCH**

**WILEY-VCH Verlag GmbH & Co. KGaA**

#### Series Editors

**Prof. Dr. Raimund Mannhold**  
Molecular Drug Research Group  
Heinrich-Heine-Universität  
Universitätsstrasse 1  
40225 Düsseldorf  
Germany  
mannhold@uni-duesseldorf.de

**Prof. Dr. Hugo Kubinyi**  
Donnersbergstrasse 9  
67256 Weisenheim am Sand  
Germany  
kubinyi@t-online.de

**Prof. Dr. Gerd Folkers**  
Collegium Helveticum  
STW/ETH Zurich  
8092 Zurich  
Switzerland  
folkers@collegium.ethz.ch

#### Volume Editor

**Dr. Nathan Brown**  
The Institute of Cancer Research  
Cancer Research UK Cancer  
Therapeutics Unit  
15 Cotswold Road  
Sutton SM2 5NG  
United Kingdom

All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:** applied for

#### British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

#### Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2012 Wiley-VCH Verlag & Co. KGaA,  
Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Composition** Thomson Digital, Noida, India

**Printing and Binding** Markono Print Media Pte Ltd, Singapore

**Cover Design** Schulz Grafik-Design, Fußgönheim

**Print ISBN:** 978-3-527-33015-7

**ePDF ISBN:** 978-3-527-65433-8

**ePub ISBN:** 978-3-527-65432-1

**mobi ISBN:** 978-3-527-65431-4

**oBook ISBN:** 978-3-527-65430-7

Printed in Singapore

Printed on acid-free paper

## Contents

<b>List of Contributors</b>	XI
<b>Preface</b>	XV
<b>A Personal Foreword</b>	XVII

### Part One Principles 1

<b>1</b>	<b>Bioisosterism in Medicinal Chemistry</b>	3
	<i>Nathan Brown</i>	
1.1	Introduction	3
1.2	Isosterism	3
1.3	Bioisosterism	6
1.4	Bioisosterism in Lead Optimization	9
1.4.1	Common Replacements in Medicinal Chemistry	9
1.4.2	Structure-Based Drug Design	9
1.4.3	Multiobjective Optimization	12
1.5	Conclusions	13
	References	14
<b>2</b>	<b>Classical Bioisosteres</b>	15
	<i>Caterina Barillari and Nathan Brown</i>	
2.1	Introduction	15
2.2	Historical Background	15
2.3	Classical Bioisosteres	17
2.3.1	Monovalent Atoms and Groups	17
2.3.2	Bivalent Atoms and Groups	17
2.3.3	Trivalent Atoms and Groups	18
2.3.4	Tetravalent Atoms	19
2.3.5	Ring Equivalents	19
2.4	Nonclassical Bioisosteres	20
2.4.1	Carbonyl Group	20
2.4.2	Carboxylic Acid	21
2.4.3	Hydroxyl Group	22
2.4.4	Catechol	22

2.4.5	Halogens	23
2.4.6	Amide and Esters	24
2.4.7	Thiourea	25
2.4.8	Pyridine	26
2.4.9	Cyclic Versus Noncyclic Systems	27
2.5	Summary	27
	References	27
<b>3</b>	<b>Consequences of Bioisosteric Replacement</b>	<b>31</b>
	<i>Dennis A. Smith and David S. Millan</i>	
3.1	Introduction	31
3.2	Bioisosteric Groupings to Improve Permeability	32
3.3	Bioisosteric Groupings to Lower Intrinsic Clearance	40
3.4	Bioisosteric Groupings to Improve Target Potency	43
3.5	Conclusions and Future Perspectives	47
	References	49
<b>Part Two</b>	<b>Data</b>	<b>53</b>
<b>4</b>	<b>BIOSTER: A Database of Bioisosteres and Bioanalogues</b>	<b>55</b>
	<i>István Ujváry and Julian Hayward</i>	
4.1	Introduction	55
4.2	Historical Overview and the Development of BIOSTER	56
4.2.1	Representation of Chemical Transformations for Reaction Databases	56
4.2.2	The Concept of “Biosteric Transformation”	57
4.2.3	Other Analogue and Bioisostere Databases	58
4.3	Description of BIOSTER Database	59
4.3.1	Coverage and Selection Criteria	59
4.3.2	Sources	59
4.3.3	Description of the Layout of Database Records	60
4.3.3.1	ID Code	60
4.3.3.2	Biosteric Transformation	60
4.3.3.3	Citation(s)	62
4.3.3.4	Activity	63
4.3.3.5	Fragments	63
4.3.3.6	Component Molecules and Fragments	64
4.4	Examples	64
4.4.1	Benzodioxole Bioisosteres	65
4.4.2	Phenol Bioisosteres	66
4.4.3	Ketoamides	66
4.5	Applications	69
4.6	Summary	70
4.7	Appendix	70
	References	71

<b>5</b>	<b>Mining the Cambridge Structural Database for Bioisosteres</b>	<b>75</b>
	<i>Colin R. Groom, Tjelvar S. G. Olsson, John W. Liebeschuetz, David A. Bardwell, Ian J. Bruno, and Frank H. Allen</i>	
5.1	Introduction	75
5.2	The Cambridge Structural Database	76
5.3	The Cambridge Structural Database System	78
5.3.1	ConQuest	78
5.3.2	Mercury	78
5.3.3	WebCSD	79
5.3.4	Knowledge-Based Libraries Derived from the CSD	80
5.4	The Relevance of the CSD to Drug Discovery	83
5.5	Assessing Bioisosteres: Conformational Aspects	84
5.6	Assessing Bioisosteres: Nonbonded Interactions	86
5.7	Finding Bioisosteres in the CSD: Scaffold Hopping and Fragment Linking	91
5.7.1	Scaffold Hopping	91
5.7.2	Fragment Linking	92
5.8	A Case Study: Bioisosterism of 1 <i>H</i> -Tetrazole and Carboxylic Acid Groups	94
5.8.1	Conformational Mimicry	94
5.8.2	Intermolecular Interactions	94
5.9	Conclusions	97
	References	98
<b>6</b>	<b>Mining for Context-Sensitive Bioisosteric Replacements in Large Chemical Databases</b>	<b>103</b>
	<i>George Papadatos, Michael J. Bodkin, Valerie J. Gillet, and Peter Willett</i>	
6.1	Introduction	103
6.2	Definitions	104
6.3	Background	105
6.4	Materials and Methods	109
6.4.1	Human Microsomal Metabolic Stability	109
6.4.2	Data Preprocessing	109
6.4.3	Generation of Matched Molecular Pairs	110
6.4.4	Context Descriptors	111
6.4.4.1	Whole Molecule Descriptors	111
6.4.4.2	Local Environment Descriptors	112
6.4.5	Binning of $\Delta P$ Values	112
6.4.6	Charts and Statistics	112
6.5	Results and Discussion	113
6.5.1	General Considerations	123
6.6	Conclusions	124
	References	125

**Part Three Methods** 129**7 Physicochemical Properties** 131*Peter Ertl*

- 7.1 Introduction 131
- 7.2 Methods to Identify Bioisosteric Analogues 132
- 7.3 Descriptors to Characterize Properties of Substituents and Spacers 132
- 7.4 Classical Methods for Navigation in the Substituent Space 135
- 7.5 Tools to Identify Bioisosteric Groups Based on Similarity in Their Properties 136
- 7.6 Conclusions 138
- References 138

**8 Molecular Topology** 141*Nathan Brown*

- 8.1 Introduction 141
- 8.2 Controlled Fuzziness 141
- 8.3 Graph Theory 142
- 8.4 Data Mining 144
- 8.4.1 Graph Matching 144
- 8.4.2 Fragmentation Methods 145
- 8.5 Topological Pharmacophores 146
- 8.6 Reduced Graphs 149
- 8.7 Summary 151
- References 152

**9 Molecular Shape** 155*Pedro J. Ballester and Nathan Brown*

- 9.1 Methods 156
- 9.1.1 Superposition-Based Shape Similarity Methods 156
- 9.1.2 Superposition-Free Shape Similarity Methods 158
- 9.1.3 Choosing a Shape Similarity Technique for a Particular Project 160
- 9.2 Applications 161
- 9.3 Future Prospects 164
- References 165

**10 Protein Structure** 167*James E. J. Mills*

- 10.1 Introduction 167
- 10.2 Database of Ligand-Protein Complexes 168
- 10.2.1 Extraction of Ligands 168
- 10.2.2 Assessment of Ligand and Protein Criteria 169

- 10.2.3 Cavity Generation 170
- 10.2.4 Generation and Validation of SMILES String 170
- 10.2.5 Generation of FASTA Sequence Files 171
- 10.2.6 Identification of Intermolecular Interactions 172
- 10.3 Generation of Ideas for Bioisosteres 173
  - 10.3.1 Substructure Search 173
  - 10.3.2 Sequence Search 175
  - 10.3.3 Binding Pocket Superposition 175
  - 10.3.4 Bioisostere Identification 176
- 10.4 Context-Specific Bioisostere Generation 177
- 10.5 Using Structure to Understand Common Bioisosteric Replacements 178
- 10.6 Conclusions 180
  - References 180

#### **Part Four Applications 183**

- 11 The Drug Guru Project 185**  
*Kent D. Stewart, Jason Shanley, Karam B. Alsayyed Ahmed, and J. Phillip Bowen*
  - 11.1 Introduction 185
  - 11.2 Implementation of Drug Guru 187
  - 11.3 Bioisosteres 188
  - 11.4 Application of Drug Guru 194
  - 11.5 Quantitative Assessment of Drug Guru Transformations 195
  - 11.6 Related Work 197
  - 11.7 Summary: The Abbott Experience with the Drug Guru Project 197
    - References 198
  
- 12 Bioisosteres of an NPY-Y5 Antagonist 199**  
*Nicholas P. Barton and Benjamin R. Bellenie*
  - 12.1 Introduction 199
  - 12.2 Background 199
  - 12.3 Potential Bioisostere Approaches 201
  - 12.4 Template Molecule Preparation 204
  - 12.5 Database Molecule Preparation 206
  - 12.6 Alignment and Scoring 206
  - 12.7 Results and Monomer Selection 207
  - 12.8 Synthesis and Screening 208
  - 12.9 Discussion 209
  - 12.10 SAR and Developability Optimization 211
  - 12.11 Summary and Conclusion 214
    - References 214



<b>13</b>	<b>Perspectives from Medicinal Chemistry</b>	<b>217</b>
	<i>Nicholas A. Meanwell, Marcus Gastreich, Matthias Rarey, Mike Devereux, Paul L.A. Popelier, Gisbert Schneider, and Peter Willett</i>	
13.1	Introduction	217
13.2	Pragmatic Bioisostere Replacement in Medicinal Chemistry: A Software Maker's Viewpoint	219
13.3	The Role of Quantum Chemistry in Bioisostere Prediction	221
13.4	Learn from "Naturally Drug-Like" Compounds	223
13.5	Bioisosterism at the University of Sheffield	224
	References	227
	<b>Index</b>	<b>231</b>